Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Abstract
Oncolytic viruses (OVs) are naturally occurring or genetically engineered viruses that selectively target and destroy cancer cells. They act through multiple mechanisms, including direct tumor cell lysis, stimulation of immune‐mediated cytotoxicity, and modulation of the tumor microenvironment (TME). Recent studies have shown that, beyond their direct oncolytic activity, OVs also influence the immune landscape by modulating the expression of PD‐1/PD‐L1 axis. In many cases, OVs trigger the release of proinflammatory cytokines, leading to increased PD‐L1 levels on immune cells. This upregulation plays a key role in modulating the TME and shaping immune checkpoint signaling. While there is also evidence that OVs can directly reduce PD‐L1 expression on tumor cells, the most prominent effect appears to be the boost in PD‐L1 expression. This shift is thought to be crucial in influencing how the immune system responds to tumors. These changes could modulate PD‐L1‐mediated immune suppression and alter the exhaustion and anergy rate of the effector tumor‐specific T cells infiltrated into the TME. This review discusses how OVs influence PD‐1 and PD‐L1 expression, with a focus on innate and adaptive immune activation, interferon signaling pathways, and engineered OVs designed to express immunomodulatory cytokines and chemokines. We explore how these mechanisms can be leveraged to enhance antitumor immunity, particularly in combination with ICIs. Furthermore, we discuss the potential of OVs to remodel the TME, modulate PD‐L1 expression, and promote immune‐mediated tumor clearance. Overall, this review highlights the evolving role of OVs in cancer therapy and their potential to augment the effectiveness of current immunotherapeutic strategies.Keywords
This publication has 134 references indexed in Scilit:
- Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based ApproachesDigestive Diseases and Sciences, 2025
- 1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II studyAnnals of Oncology, 2023
- Application of oncolytic virus in tumor therapyJournal of Medical Virology, 2023
- Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasionJournal of Medical Virology, 2023
- A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA studyCancer Immunology, Immunotherapy, 2022
- Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With PembrolizumabJAMA Oncology, 2020
- Oncolytic Viruses: Priming Time for Cancer ImmunotherapyBioDrugs, 2019
- A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanomaCancer Chemotherapy and Pharmacology, 2017
- Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9Cancer Letters, 2016
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992